Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $60.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $14.66M, a 3333.72% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $46.29M, a 102773.33% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $9.45M, a 1849.28% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $4.99M, a 3894.40% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $14.92M, a 1239.23% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.11M, a 2321.74% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $46.00K.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.30M, a 18.18% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $60.95M 10-Q · filed 2026-08-04 | $70.41M derived: sum of 3 quarters · filed 2026-08-04 | $75.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $46.29M 10-Q · filed 2026-05-05 | $55.75M derived: sum of 2 quarters · filed 2026-05-05 | $60.74M derived: sum of 3 quarters · filed 2026-05-05 | $61.17M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $14.45M derived: sum of 2 quarters · filed 2026-03-09 | $14.87M derived: sum of 3 quarters · filed 2026-03-09 | $14.92M 10-K · filed 2026-03-09 |
| 2025-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.42M derived: sum of 2 quarters · filed 2025-11-05 | $5.46M 10-Q · filed 2025-11-05 | $5.95M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | $427.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $472.00K 10-Q · filed 2025-08-07 | $957.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.08M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $45.00K 10-Q · filed 2025-05-12 | $530.00K derived: sum of 2 quarters · filed 2025-05-12 | $655.00K derived: sum of 3 quarters · filed 2025-05-12 | $694.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | $485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $610.00K derived: sum of 2 quarters · filed 2025-03-11 | $649.00K derived: sum of 3 quarters · filed 2025-03-11 | $1.11M 10-K · filed 2025-03-11 |
| 2024-09-30 | $125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $164.00K derived: sum of 2 quarters · filed 2024-11-07 | $629.00K 10-Q · filed 2024-11-07 | $629.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $504.00K 10-Q · filed 2024-08-08 | $504.00K derived: sum of 3 quarters · filed 2024-08-08 | |
| 2024-03-31 | $465.00K 10-Q · filed 2024-05-09 | $465.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $46.00K 10-K · filed 2024-03-21 | ||
| 2023-09-30 | $46.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $1.30M 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $1.10M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |